Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).

Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y.

Br J Cancer. 2019 Jul 9. doi: 10.1038/s41416-019-0518-2. [Epub ahead of print]

PMID:
31285591
2.

Comprehensive genetic analysis of cholangiolocellular carcinoma with a co-existent hepatocellular carcinoma (HCC)-like area and metachronous HCC.

Kawai-Kitahata F, Asahina Y, Kaneko S, Tsuchiya J, Sato A, Miyoshi M, Tsunoda T, Inoue-Shinomiya E, Murakawa M, Nitta S, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Tanabe M, Sugawara E, Takemoto A, Ojima H, Sakamoto M, Muraoka M, Takano S, Maekawa S, Enomoto N, Watanabe M.

Hepatol Res. 2019 Jul 1. doi: 10.1111/hepr.13403. [Epub ahead of print]

PMID:
31261448
3.

Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival.

Masugi Y, Abe T, Ueno A, Fujii-Nishimura Y, Ojima H, Endo Y, Fujita Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M.

Mod Pathol. 2019 Jun 11. doi: 10.1038/s41379-019-0291-z. [Epub ahead of print]

PMID:
31186528
4.

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.

Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H.

Cell Rep. 2019 Apr 23;27(4):1265-1276.e4. doi: 10.1016/j.celrep.2019.03.088.

5.

Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features.

Hatano M, Ojima H, Masugi Y, Tsujikawa H, Hiraoka N, Kanai Y, Shimada K, Shinoda M, Sakamoto M.

Hum Pathol. 2019 Apr;86:222-232. doi: 10.1016/j.humpath.2018.11.024. Epub 2018 Dec 28.

PMID:
30597153
6.

Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer.

Kusumoto T, Ishiguro M, Nakatani E, Yoshida M, Inoue T, Nakamoto Y, Shiomi A, Takagane A, Sunami E, Shinozaki H, Takii Y, Maeda A, Ojima H, Hashida H, Mukaiya M, Yokoyama T, Nakamura M, Munemoto Y, Sugihara K.

ESMO Open. 2018 Oct 7;3(6):e000428. doi: 10.1136/esmoopen-2018-000428. eCollection 2018.

7.

Epigenome mapping of human normal purified hepatocytes: personal epigenome variation and genome-epigenome correlation.

Arai E, Miura F, Totoki Y, Yamashita S, Tian Y, Gotoh M, Ojima H, Nakagawa H, Takahashi Y, Nakamura H, Hama N, Kato M, Kimura H, Suzuki Y, Ito T, Shibata T, Kanai Y.

Epigenomics. 2018 Jul;10(7):955-979. doi: 10.2217/epi-2017-0111. Epub 2018 Jul 4.

8.

Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.

Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M.

Hepatology. 2018 Sep;68(3):1025-1041. doi: 10.1002/hep.29904. Epub 2018 Jul 25.

PMID:
29603348
9.

The potentiality of laparoscopic partial liver excisional biopsy using analysis of the liver surface based on preoperative 3D simulation imaging: A case report.

Ei S, Itano O, Yoshida H, Ojima H, Shimoda M, Uchida H, Maeda S, Kumamoto Y, Aiko S.

Int J Surg Case Rep. 2018;45:33-37. doi: 10.1016/j.ijscr.2018.03.019. Epub 2018 Mar 16.

10.

Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).

Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T; JASPAC 01 Study Group.

Eur J Cancer. 2018 Apr;93:79-88. doi: 10.1016/j.ejca.2018.01.081. Epub 2018 Mar 20.

PMID:
29477795
11.

PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.

Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.

Jpn J Clin Oncol. 2018 Apr 1;48(4):396-399. doi: 10.1093/jjco/hyy011.

PMID:
29474549
12.

Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells.

Fujii-Nishimura Y, Yamazaki K, Masugi Y, Douguchi J, Kurebayashi Y, Kubota N, Ojima H, Kitago M, Shinoda M, Hashiguchi A, Sakamoto M.

Pathol Int. 2018 Apr;68(4):214-223. doi: 10.1111/pin.12641. Epub 2018 Feb 19.

PMID:
29457853
13.

Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system.

Saito Y, Nakaoka T, Muramatsu T, Ojima H, Sukeda A, Sugiyama Y, Uchida R, Furukawa R, Kitahara A, Sato T, Kanai Y, Saito H.

Sci Rep. 2018 Feb 12;8(1):2821. doi: 10.1038/s41598-018-21121-6.

14.

The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses.

Kanai Y, Nishihara H, Miyagi Y, Tsuruyama T, Taguchi K, Katoh H, Takeuchi T, Gotoh M, Kuramoto J, Arai E, Ojima H, Shibuya A, Yoshida T, Akahane T, Kasajima R, Morita KI, Inazawa J, Sasaki T, Fukayama M, Oda Y.

Pathol Int. 2018 Feb;68(2):63-90. doi: 10.1111/pin.12631.

PMID:
29431262
15.

Liver atrophy after percutaneous transhepatic portal embolization occurs in two histological phases: Hepatocellular atrophy followed by apoptosis.

Iwao Y, Ojima H, Kobayashi T, Kishi Y, Nara S, Esaki M, Shimada K, Hiraoka N, Tanabe M, Kanai Y.

World J Hepatol. 2017 Nov 18;9(32):1227-1238. doi: 10.4254/wjh.v9.i32.1227.

16.

Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.

Hamaguchi T, Shimada Y, Mizusawa J, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Takiguchi N, Yatsuoka T, Takii Y, Ojima H, Masuko H, Kubo Y, Mishima H, Yamaguchi T, Bando H, Sato T, Kato T, Nakamura K, Fukuda H, Moriya Y.

Lancet Gastroenterol Hepatol. 2018 Jan;3(1):47-56. doi: 10.1016/S2468-1253(17)30297-2. Epub 2017 Oct 24.

PMID:
29079411
17.

Cortical Activation Patterns Evoked by Temporally Asymmetric Sounds and Their Modulation by Learning.

Horikawa J, Ojima H.

eNeuro. 2017 Apr 21;4(2). pii: ENEURO.0241-16.2017. doi: 10.1523/ENEURO.0241-16.2017. eCollection 2017 Mar-Apr. Erratum in: eNeuro. 2017 May 25;4(3):.

18.

Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.

Kuramoto J, Arai E, Tian Y, Funahashi N, Hiramoto M, Nammo T, Nozaki Y, Takahashi Y, Ito N, Shibuya A, Ojima H, Sukeda A, Seki Y, Kasama K, Yasuda K, Kanai Y.

Carcinogenesis. 2017 Mar 1;38(3):261-270. doi: 10.1093/carcin/bgx005.

19.

Auditory-visual integration in fields of the auditory cortex.

Kubota M, Sugimoto S, Hosokawa Y, Ojima H, Horikawa J.

Hear Res. 2017 Mar;346:25-33. doi: 10.1016/j.heares.2017.01.012. Epub 2017 Jan 21.

PMID:
28115229
20.

Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST.

Kanda T, Masuzawa T, Hirai T, Ikawa O, Takagane A, Hata Y, Ojima H, Sodeyama H, Mochizuki I, Ishikawa T, Kagimura T, Nishida T.

Jpn J Clin Oncol. 2017 Apr 1;47(4):369-372. doi: 10.1093/jjco/hyw203.

PMID:
28073945
21.

Genes involved in development and differentiation are commonly methylated in cancers derived from multiple organs: a single-institutional methylome analysis using 1007 tissue specimens.

Ohara K, Arai E, Takahashi Y, Ito N, Shibuya A, Tsuta K, Kushima R, Tsuda H, Ojima H, Fujimoto H, Watanabe SI, Katai H, Kinoshita T, Shibata T, Kohno T, Kanai Y.

Carcinogenesis. 2017 Mar 1;38(3):241-251. doi: 10.1093/carcin/bgw209.

22.

Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.

Sakamoto M, Tsujikawa H, Effendi K, Ojima H, Harada K, Zen Y, Kondo F, Nakano M, Kage M, Sumida Y, Hashimoto E, Yamada G, Okanoue T, Koike K.

Pathol Int. 2017 Jan;67(1):1-7. doi: 10.1111/pin.12485. Epub 2016 Dec 20. Review. No abstract available.

PMID:
27995687
23.

[Information Processing in the Auditory Ventral Stream].

Fukushima M, Ojima H.

Brain Nerve. 2016 Nov;68(11):1371-1378. Review. Japanese.

PMID:
27852027
24.

Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies.

Ojima H, Yamagishi S, Shimada K, Shibata T.

World J Gastroenterol. 2016 Oct 28;22(40):9035-9038.

25.

Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma.

Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y, Kondo T.

Clin Proteomics. 2016 Oct 24;13:28. eCollection 2016.

26.

Proteomic study of hepatocellular carcinoma using a novel modified aptamer-based array (SOMAscan™) platform.

Qiao Z, Pan X, Parlayan C, Ojima H, Kondo T.

Biochim Biophys Acta Proteins Proteom. 2017 Apr;1865(4):434-443. doi: 10.1016/j.bbapap.2016.09.011. Epub 2016 Sep 20.

PMID:
27663888
27.

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group.

Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2.

PMID:
27265347
28.

Erratum: Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.

Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Wardell CP, Hayami S, Nakamura T, Aikata H, Arihiro K, Boroevich KA, Abe T, Nakano K, Maejima K, Sasaki-Oku A, Ohsawa A, Shibuya T, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Ojima H, Hiraoka N, Okusaka T, Kubo M, Marubashi S, Yamada T, Hirano S, Yamamoto M, Ohdan H, Shimada K, Ishikawa O, Yamaue H, Chayama K, Miyano S, Aburatani H, Shibata T, Nakagawa H.

Nat Genet. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700a. No abstract available.

PMID:
27230686
29.

Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.

Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Wardell CP, Hayami S, Nakamura T, Aikata H, Arihiro K, Boroevich KA, Abe T, Nakano K, Maejima K, Sasaki-Oku A, Ohsawa A, Shibuya T, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Ojima H, Hiraoka N, Okusaka T, Kubo M, Marubashi S, Yamada T, Hirano S, Yamamoto M, Ohdan H, Shimada K, Ishikawa O, Yamaue H, Chayama K, Miyano S, Aburatani H, Shibata T, Nakagawa H.

Nat Genet. 2016 May;48(5):500-9. doi: 10.1038/ng.3547. Epub 2016 Apr 11. Erratum in: Nat Genet. 2016 May 27;48(6):700.

PMID:
27064257
30.

Recognition of Modified Conditioning Sounds by Competitively Trained Guinea Pigs.

Ojima H, Horikawa J.

Front Behav Neurosci. 2016 Jan 26;9:373. doi: 10.3389/fnbeh.2015.00373. eCollection 2015.

31.

Early hepatocellular carcinoma with high-grade atypia in small vaguely nodular lesions.

Ojima H, Masugi Y, Tsujikawa H, Emoto K, Fujii-Nishimura Y, Hatano M, Kawaida M, Itano O, Kitagawa Y, Sakamoto M.

Cancer Sci. 2016 Apr;107(4):543-50. doi: 10.1111/cas.12893. Epub 2016 Mar 18.

32.

Genomic spectra of biliary tract cancer.

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T.

Nat Genet. 2015 Sep;47(9):1003-10. doi: 10.1038/ng.3375. Epub 2015 Aug 10.

PMID:
26258846
33.

Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.

Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.

Mol Cancer Ther. 2015 Sep;14(9):1985-93. doi: 10.1158/1535-7163.MCT-15-0069. Epub 2015 Jul 3.

34.

[Mucinous cystic neoplasm (MCN) of the liver].

Ojima H.

Nihon Rinsho. 2015 Mar;73 Suppl 3:792-6. Japanese. No abstract available.

PMID:
25857137
35.

[The excision repair cross-complementation group 1].

Sakamoto Y, Ojima H, Morizane C, Kanai Y, Okusaka T.

Nihon Rinsho. 2015 Mar;73 Suppl 3:485-90. Japanese. No abstract available.

PMID:
25857073
36.

Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.

Miyazaki T, Ojima H, Fukuchi M, Sakai M, Sohda M, Tanaka N, Suzuki S, Ieta K, Saito K, Sano A, Yokobori T, Inose T, Nakajima M, Kato H, Kuwano H.

Ann Surg Oncol. 2015 Oct;22(11):3653-8. doi: 10.1245/s10434-015-4440-4. Epub 2015 Feb 18.

PMID:
25691281
37.

Lysine Demethylase LSD1 Coordinates Glycolytic and Mitochondrial Metabolism in Hepatocellular Carcinoma Cells.

Sakamoto A, Hino S, Nagaoka K, Anan K, Takase R, Matsumori H, Ojima H, Kanai Y, Arita K, Nakao M.

Cancer Res. 2015 Apr 1;75(7):1445-56. doi: 10.1158/0008-5472.CAN-14-1560. Epub 2015 Feb 3.

38.

Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.

Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, Nakamura T, Ueno M, Ariizumi S, Nguyen HH, Shigemizu D, Abe T, Boroevich KA, Nakano K, Sasaki A, Kitada R, Maejima K, Yamamoto Y, Tanaka H, Shibuya T, Shibata T, Ojima H, Shimada K, Hayami S, Shigekawa Y, Aikata H, Ohdan H, Marubashi S, Yamada T, Kubo M, Hirano S, Ishikawa O, Yamamoto M, Yamaue H, Chayama K, Miyano S, Tsunoda T, Nakagawa H.

Nat Commun. 2015 Jan 30;6:6120. doi: 10.1038/ncomms7120.

PMID:
25636086
39.

A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.

Yamazaki K, Kuwano H, Ojima H, Otsuji T, Kato T, Shimada K, Hyodo I, Nishina T, Shirao K, Esaki T, Ohishi T, Denda T, Takeuchi M, Boku N.

Cancer Chemother Pharmacol. 2015 Mar;75(3):569-77. doi: 10.1007/s00280-015-2676-0. Epub 2015 Jan 10.

PMID:
25575764
40.

Relationship between functional end-to-end anastomosis for colon cancer and surgical site infections.

Ojima H, Sohda M, Ando H, Sano A, Fukai Y, Ogawa A, Mochida Y, Kuwano H.

Surg Today. 2015 Dec;45(12):1489-92. doi: 10.1007/s00595-015-1110-x. Epub 2015 Jan 9.

PMID:
25572433
41.

Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.

Miyazaki T, Sohda M, Tanaka N, Suzuki S, Ieta K, Sakai M, Sano A, Yokobori T, Inose T, Nakajima M, Fukuchi M, Ojima H, Kato H, Kuwano H.

Cancer Chemother Pharmacol. 2015 Mar;75(3):449-55. doi: 10.1007/s00280-014-2659-6. Epub 2014 Dec 28.

PMID:
25544126
42.

Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma.

Oguro S, Esaki M, Kishi Y, Nara S, Shimada K, Ojima H, Kosuge T.

Ann Surg Oncol. 2015;22(6):1915-24. doi: 10.1245/s10434-014-4232-2. Epub 2014 Nov 18.

PMID:
25404474
43.

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.

Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H, Yamamoto S, Shinbrot E, Hama N, Lehmkuhl M, Hosoda F, Arai Y, Walker K, Dahdouli M, Gotoh K, Nagae G, Gingras MC, Muzny DM, Ojima H, Shimada K, Midorikawa Y, Goss JA, Cotton R, Hayashi A, Shibahara J, Ishikawa S, Guiteau J, Tanaka M, Urushidate T, Ohashi S, Okada N, Doddapaneni H, Wang M, Zhu Y, Dinh H, Okusaka T, Kokudo N, Kosuge T, Takayama T, Fukayama M, Gibbs RA, Wheeler DA, Aburatani H, Shibata T.

Nat Genet. 2014 Dec;46(12):1267-73. doi: 10.1038/ng.3126. Epub 2014 Nov 2.

PMID:
25362482
44.

Down-regulation of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor by HEXIM1 attenuates myocardial angiogenesis in hypoxic mice.

Yoshikawa N, Shimizu N, Ojima H, Kobayashi H, Hosono O, Tanaka H.

Biochem Biophys Res Commun. 2014 Oct 24;453(3):600-5. doi: 10.1016/j.bbrc.2014.09.135. Epub 2014 Oct 6.

PMID:
25301555
45.

Primary esophageal adenocarcinoma with distant metastasis to the skeletal muscle.

Sohda M, Ojima H, Sano A, Fukai Y, Kuwano H.

Int Surg. 2014 Sep-Oct;99(5):650-5. doi: 10.9738/INTSURG-D-13-00166.1.

46.

A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.

Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, Kimura A, Kogure N, Yokobori T, Ohno T, Kuwano H.

J Surg Oncol. 2014 Dec;110(8):942-6. doi: 10.1002/jso.23773. Epub 2014 Aug 28.

PMID:
25164620
47.

Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.

Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, Sugiyama K, Suzuki H, Arai E, Ojima H, Kanai Y, Saito H.

Cancer Sci. 2014 Oct;105(10):1254-60. doi: 10.1111/cas.12498. Epub 2014 Sep 25.

48.

Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)".

Nakanuma Y, Sato Y, Ojima H, Kanai Y, Aishima S, Yamamoto M, Ariizumi S, Furukawa T, Hayashi H, Unno M, Ohta T; Hepatolithiasis Subdivision of Intractable Hepatobiliary Diseases Study Group of Japan (Chairman, Hirohito Tsubouchi).

Int J Clin Exp Pathol. 2014 May 15;7(6):3112-22. eCollection 2014.

49.

Global PROTOMAP profiling to search for biomarkers of early-recurrent hepatocellular carcinoma.

Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, Nakayama H, Takahashi N, Kosuge T, Isobe T, Kondo T.

J Proteome Res. 2014 Nov 7;13(11):4847-58. doi: 10.1021/pr500262p. Epub 2014 Jul 7.

PMID:
24967658
50.

Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.

Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T.

Jpn J Clin Oncol. 2014 Jun;44(6):570-8. doi: 10.1093/jjco/hyu045. Epub 2014 Apr 21.

PMID:
24755544

Supplemental Content

Support Center